Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 5, 2012
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophiliaHenrik Agersø, Mikael Tranholm
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 7, 2003
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivativeHenrik Agersø, Paolo Vicini
CPT: Pharmacometrics & Systems Pharmacology|September 20, 2022
Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradoxNiels Rode Kristensen, Henrik Agersø
Basic & Clinical Pharmacology & Toxicology|April 17, 2013
Nephrectomized and hepatectomized animal models as tools in preclinical pharmacokineticsBill Vestergaard, Henrik Agersø, Jens Lykkesfeldt
Thrombosis Research|April 16, 2014
The kidneys play an important role in the clearance of rFVIIa in ratsBill Vestergaard, Rupa S Appa, Jens Lykkesfeldt, et al.
Clinical Pharmacokinetics|April 20, 2018
Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I TrialsRasmus Vestergaard Juul, Michael Højby Rasmussen, Henrik Agersø, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 1, 2003
The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogsHenrik Agersø, Wolfgang Koechling, Magnus Knutsson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2020
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly SomapacitanRasmus Juul Kildemoes, Michael Højby Rasmussen, Henrik Agersø, et al.
Diabetes, Obesity & Metabolism|February 4, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approachTheodoros Papathanasiou, Anders Strathe, Henrik Agersø, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 13, 2006
Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blockerPravin R Jadhav, Henrik Agersø, Christoffer W Tornøe, et al.
Pageof 4